Business Wire

New data support the use of LIXIANA ® (edoxaban) in complex patient populations with atrial fibrillation (AF)


Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced a wealth of new edoxaban data being presented at ESC Congress 2021, organised by the European Society of Cardiology. These include insights from routine clinical practice via the ETNA-AF Registry, which reaffirm the efficacy and safety profile of edoxaban seen in randomised clinical trials across a range of atrial fibrillation (AF) patient populations. In addition, results from the ENVISAGE-TAVI AF study, presented as a Hot Line session during the congress, compared the efficacy and safety of edoxaban with vitamin-K-antagonists (VKA) in patients with AF having undergone successful transcatheter aortic valve implantation (TAVI).1 Findings from the trial were simultaneously published in The New England Journal of Medicine (NEJM).

The revised 2021 EHRA* Practical Guide on the Use of NOACsin Patients with Atrial Fibrillation (AF), which was published earlier this year (April), recommends the use of NOACs as first-line treatment of patients with AF and includes specific guidance around treating complex AF patient populations, such as those with different levels of frailty and those with renal impairment.2 The data presented today further complement the recommendations of the Practical Guide for the treatment of AF patients using NOACs.

“These new data, in addition to the recently updated EHRA Practical Guide on the use of NOACs in AF, provide long-awaited scientific evidence that the clinical community will welcome as a huge support in helping treat these complex patient populations with AF,” said Prof. Hein Heidbuchel, Chair of Cardiology at Antwerp University, Belgium, and immediate Past-President of the European Heart Rhythm Association (EHRA). “It is acknowledged across the world now that NOACs are the preferred choice of treatment for patients with AF. Having additional data to help guide healthcare professionals in the specifics of anticoagulating these patient populations will bring further clarity and confidence to the clinical community.”

ETNA-AF-Europe Registry: Worsening renal function (WRF) and frailty

Key ePosters presented from the ETNA-AF-Europe Registry include the evaluation of the degree of worsening renal function (WRF) in AF patients treated with edoxaban after two-years of follow-up and an investigation of clinical outcomes of patients with vs. without WRF. Results from 9,084 patients included in this subgroup analysis showed that there is a low risk of WRF in AF patients treated with edoxaban over a two-year period, with the majority of the edoxaban-treated patients not experiencing WRF (89.9%). Results also found that:3

  • Patients with WRF had higher mortality than those without (all-cause mortality: 3.78% vs. 1.90%; cardiovascular death: 2.06% vs. 0.92%, respectively).
  • Patients with WRF had numerically higher major bleeding and stroke rates vs. those without WRF.
  • Importantly, intracranial haemorrhage rates remained low irrespective of WRF (0.17% in those with WRF vs. 0.19% in those without).

A second key ePoster analysed effectiveness and safety outcomes in subjectively vs. objectively frail patients in the overall population. Results showed that the presence of frailty (either subjective or objective) predicts cardiovascular (CV) events in anticoagulated patients with AF and is associated with a worse prognosis of CV events.4 These results support the idea that a comprehensive assessment of frailty could improve the routine care of patients with AF and are in line with the ESC 2020 guidelines, which highlight the importance of including assessment and evaluation of frailty into the integrated management of AF.5


In addition, results from the ENVISAGE-TAVI AF study were presented as a Hot Line session during the ESC congress 2021. In this multinational, randomised, Phase 3b study, 1,426 elderly patients with multiple comorbidities were included and followed for up to three years.1,6 The study results suggest that edoxaban is an appropriate treatment option for AF patients with severe aortic stenosis following successful TAVI.1,6 To date, this is the only sufficiently large and statistically powered study that compares a non-vitamin K antagonist oral anticoagulant (NOAC) with VKAs in AF patients after TAVI.1,6

“TAVI is an established treatment option for patients with severe aortic valve stenosis, including those with AF and multiple comorbidities,” said George Dangas, MD, PhD, Professor of Medicine (Cardiology) and Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. “In AF patients, anticoagulation is required to prevent stroke, which can be a devastating complication following TAVI. ENVISAGE-TAVI AF shows that treatment with edoxaban can be valuable in the management of this high-risk population of AF patients after TAVI.”

The study met its primary endpoint of edoxaban being noninferior to VKAs for the composite of net adverse clinical events (NACE), which included all-cause mortality, myocardial infarction, ischaemic stroke, systemic thromboembolism, valve thrombosis, and International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding.1,6 NACE occurred in 170 edoxaban-treated patients (17.3% per year) and, similarly, in 157 VKA-treated patients (16.5% per year).1,6

Edoxaban also showed numerically lower rates of all-cause mortality and ischemic stroke (two of the six individual clinical events included in the composite of NACE):1,6

  • All-cause mortality occurred in 85 edoxaban-treated patients and 93 VKA-treated patients (7.8% versus 9.1% per year, respectively).
  • Ischaemic stroke occurred in 22 edoxaban-treated patients and 28 VKA-treated patients (2.1% versus 2.8% per year, respectively).

The study did not meet its primary safety endpoint of ISTH-defined major bleeding, due to more gastrointestinal (GI) bleeds in the edoxaban arm.1,6 Other major bleeding events, including intracranial haemorrhage (ICH), as well as fatal and life-threatening bleeds, were similarly rare in both the edoxaban and VKA treatment arms.1,6

Major bleeding occurred in 98 edoxaban-treated patients and 68 VKA-treated patients (9.7% vs. 7.0% per year, respectively), which included the following:1,6

  • Major GI bleeding occurred in 56 edoxaban-treated patients and 27 VKA-treated patients (5.4% vs. 2.7% per year, respectively).
  • ICH occurred in 16 edoxaban-treated patients and 21 VKA-treated patients (1.5% vs. 2.1% per year, respectively).
  • Fatal bleeding occurred in 11 edoxaban-treated patients and 10 VKA-treated patients (1.0% vs. 1.0% per year, respectively).
  • Life threatening bleeding occurred in 17 edoxaban-treated patients and 19 VKA-treated patients (1.6% vs. 1.9% per year, respectively).

“These findings present evidence that edoxaban is an appropriate treatment option in AF patients post-TAVI, who are typically elderly and frail,” said Prof. Nicolas Van Mieghem, global co-lead investigator from Erasmus University Medical Center in Rotterdam, The Netherlands. “We found more major bleedings with edoxaban driven by more gastrointestinal bleedings that were well managed with no significant difference in intracranial or fatal bleedings.”

ETNA-AF-Europe and the ENVISAGE TAVI-AF study are part of EDOSURE, which is an extensive clinical research programme for edoxaban consisting of more than 10 randomised controlled trials, registries and non-interventional studies in a broad range of cardiovascular conditions, patient types and clinical settings in AF and venous thromboembolism (VTE), involving over 100,000 patients worldwide.

Additional edoxaban data presented at ESC Congress 2021


Age-adjusted risk factors are independently associated with an increased risk of ischaemic stroke, transient ischaemic stroke and systemic embolism in the ETNA-AF-Europe registry (link to data here)

De Caterina R, et al.

Age-adjusted risk factors are independently associated with an increased risk of major bleeding during the two-year follow-up of the ETNA-AF-Europe registry (link to data here)

Kirchhof P, et al.

Global ETNA-AF

Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: Results from the noninterventional Global ETNA-AF program (link to data here)

Dinshaw L, et al.

Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program (link to data here)

Morrone D, et al.

Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry (link to data here)

De Caterina R, et al.


Impact of polypharmacy on clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry (link to data here)

Yamashita T.

Predictors for major bleeding in elderly (75 years and over) patients with nonvalvular atrial fibrillation at high risk of bleeding: sub-analysis of the ANAFIE Registry (link to data here)

Okumura K.

Association between renal function and clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry (link to data here)

Shimizu W.

Real-world clinical outcomes and anticoagulant therapy in elderly non-valvular atrial fibrillation patients with heart failure: sub-analysis of the ANAFIE Registry (link to data here)

Ikeda S, Hiasa K, Tsutsui H.


Epistaxis in anticoagulated patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial (link to data here)

Semco RS, et al.


About ETNA-AF:


About atrial fibrillation:

About edoxaban:

About the Edoxaban Clinical Research Programme, EDOSURE:

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realise our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit

Forward-looking statements:


* European Heart Rhythm Association
† Non-Vitamin K Antagonist Oral Anticoagulants

1 Dangas G. ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation. Hot Line Presentation at ESC Congress 2021, 27–30 August.
2 Steffel J, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021; euab065,
3 Gwechenberger M, et al. Low rate of worsening renal function during 2 years of treatment with edoxaban in patients from the ETNA-AF-Europe study. Poster 84715. Presented at ESC Congress 2021.
4 Diemberger I, et al. The impact of subjective vs objective frailty on the effectiveness and safety outcomes in patients from ETNA-AF-Europe registry. Poster 84668. Presented at ESC Congress 2021.
5 Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
6 Van Mieghem NM, et al. Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement. N Engl J Med. 2021. Available at: Last accessed August 2021.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
Director PR and Portfolio Communications, Specialty Medicines
+49 151 1714 7317

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Credence MedSystems Secures $39.9 Million Financing to Enable Scaling of Innovative Drug Delivery and Connected Health Systems22.9.2021 13:03:00 CEST | Press release

Credence MedSystems, Inc. announced today that it has closed a funding round with gross proceeds of $39.9 million. Sources of funding include strategic investments from Novartis Pharma AG, Molex Ventures LLC as well as additional investors. This press release features multimedia. View the full release here: The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the Company’s platform of innovative drug delivery systems, including its connected health portfolio. “The funding comes at a great time as we take the manufacturing of our Companion and Dual Chamber systems to the next level to meet pent-up demand in the market,” stated John Merhige, Credence’s Chief Commercial Officer. Jeff Tillack, Credence’s Chief Operating Officer, added, “Our immediate focus is on implementing the production capacity to supp

UPC Hydrogen Acquires Exclusive License in Asia Pacific Region from Proton22.9.2021 13:00:00 CEST | Press release

UPC Hydrogen Pte Ltd ("UPC Hydrogen") is pleased to announce that it has acquired the exclusive license to produce hydrogen from technology developed by Proton Technologies Inc. (“Proton”) for a selection of countries in the Asia Pacific region. UPC Hydrogen is an affiliate of Renewables Asia Pacific Holdings Pte Ltd ("UPC Renewables"), a private company with 8 GW of wind, solar and storage in development, under construction or in operation across the Asia Pacific region. This press release features multimedia. View the full release here: UPC Hydrogen Acquires Exclusive License in Asia Pacific Region from Proton Technologies (Photo: Business Wire) The licenced countries include Indonesia, Vietnam, Australia, Malaysia, the Philippines, Mongolia and Myanmar. UPC Hydrogen believes that the Proton technology can produce hydrogen in these countries at a price of less than US$1.00/KG from new, plugged, abandoned or uneconomic oil well

i2c Outlines Key Growth Opportunities for UK and Europe22.9.2021 12:12:00 CEST | Press release

i2c Inc., a leading provider of digital payment and banking technology, today disclosed what it sees as key opportunities for growth in the UK and European markets, highlighting digital first, B2B commercial payments, cryptocurrency and credit as high-demand areas in which it is favorably positioned to compete. “In the past 18 months, we’ve seen increased opportunities as well as validation and acceptance of our offering in initiatives where these criteria and related use cases play heavily to customers’ requirements,” said Jonathan Vaux, general manager for UK and EU at i2c. He also noted that the driving forces appear to be a combination of continued bank digitization, a surge in payments and financial innovation in the commercial space, heightened competition among crypto players to achieve faster innovation cycles and market expansion, and broad interest in reconstructing credit as an embedded feature. According to the company, its platform features distinct characteristics that UK

TransferMate Global Payments Selects ComplyAdvantage For The Company’s Award-Winning AML And Risk Screening Solutions22.9.2021 10:57:00 CEST | Press release

Today ComplyAdvantage, a global data technology company transforming financial crime detection announced that TransferMate Global Payments, a leading global B2B-payments technology solution provider, has selected the reg tech innovator’s award-winning customer onboarding, transaction screening and monitoring solutions. This press release features multimedia. View the full release here: Charles Delingpole, CEO of ComplyAdvantage (Photo: Business Wire) Headquartered out of Kilkenny, Ireland, TransferMate is a subsidiary of Clune Technology Group founded by Terry Clune and is a leading global B2B payments technology firm enabling companies to send and receive cross-border payments faster and easier. Now more than ever before, fast growing enterprises like TransferMate are implementing the best technologies and processes not only to reduce their risk profile as it relates to financial crimes but also to help accelerate service expan

Investable Universe Launches Provocative Polar Futures Media Series22.9.2021 10:15:00 CEST | Press release

The real assets news site Investable Universe announces the launch of Polar Futures, a media series that examines the eight-nation Arctic region’s growing geopolitical importance and its potential for attracting hundreds of billions of dollars in direct investment to develop the region and its bounty of natural resources. This press release features multimedia. View the full release here: Institutional investors, pension funds and other investors are eyeing the potential of developing infrastructure, shipping, logistics, telecommunications, mining, aquaculture and marine resources and of incubating technologies that aid the transition to renewable energy. Additionally, new trans-Arctic shipping lanes made more accessible by climate change will focus competing political and military interests on the polar zone. Nuanced insights from pivotal figures Against this fluid strategic backdrop, the weekly newsletter and podcast series, c

Aqara Introduces Smart Roller Blind Retrofit Solution22.9.2021 10:00:00 CEST | Press release

Aqara, a provider for smart home products, announced the launch of the Aqara Roller Shade Driver E1, a retrofit roller shade controller to automate the existing beaded chain roller shades. The roller shade driver fits beaded cord roller shades with the bead thickness of 3 - 6 millimeter, and works with both plastic and metal beads. The driver has been available on Amazon UK starting from September 22, 2021, and it is expected to land on Amazon France in the next few weeks. It will also be made available via authorized Aqara retailers in Europe and Asia in the following months. Shades are necessary for almost all homes, as they block harmful UV rays, save energy (for ACs and lights) and protect privacy. Automated shades save users the trouble of manually controlling the shades day in and day out, while helping to cut energy bills and enhance indoor comfort. The Roller Shade Driver E1 provides a quick, easy and cost-effective way to automate the existing roller blinds. The installation i

Flawed: Cayman Finance Challenges Credibility Of Tax Justice Network’s Biannual Financial Secrecy Index22.9.2021 09:10:00 CEST | Press release

Cayman Finance has today released a new study that critically assesses the methodology and data used to assess the Cayman Islands in Tax Justice Network’s (TJN) ‘Financial Secrecy Index’ (FSI). Significant flaws in TJN’s choice of data and scoring have rendered the 2020 report an unreliable source for accurate information about the Cayman Islands financial services industry. Future TJN reports’ will also lack credibility without critical changes in the application of their own methodology – and Cayman Finance will continue to scrutinise and analyse future editions to ensure continued accountability. Ahead of the anticipated publication of the other TJN reports this fall, Cayman Finance commissioned the review to analyse the calculations of the previous report published in 2020, which incorrectly placed the Cayman Islands first globally in its secrecy ranking. This analysis, by accomplished economist Julian Morris, identified significant flaws in how TJN applied its own original methodo